(Q33981431)

30 July 2017

title

Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections (English)

1 reference

30 July 2017

G Siami

1

1 reference

30 July 2017

N Christou

2

1 reference

30 July 2017

I Eiseman

3

1 reference

30 July 2017

K J Tack

4

1 reference

30 July 2017

Severe Skin and Soft Tissue Infections Study Group

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Antimicrobial Agents and Chemotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

45

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

525-531

1 reference

Fluoroquinolone treatment of skin and skin structure infections

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Expanded activity and utility of the new fluoroquinolones: a review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Wound healing in diabetes. Outcome and costs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Initial clinical experience with clinafloxacin in the treatment of serious infections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Treatment of skin and soft-tissue infections.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Safety and tolerability of fluoroquinolones.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Optimum outpatient therapy of skin and skin structure infections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Quinolone resistance. Susceptibility data from a 300-bed community hospital

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Microbiology and antimicrobial therapy of diabetic foot infections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Review of qoinolones in the treatment of infections of the skin and skin structure

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-μg disks

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90322

Systemic antimicrobial therapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime

29 October 2018

1 reference

12 December 2020

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

1 reference

12 December 2020

Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens

1 reference

12 December 2020

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin

1 reference

12 December 2020

Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin

1 reference

12 December 2020

Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

12 December 2020

Susceptibility survey of piperacillin alone and in the presence of tazobactam

1 reference

12 December 2020

10.1128/AAC.45.2.525-531.2001

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference